AASLD News:半乳糖凝集素治疗学“（高尔特）摘要接受为口头报

StephenW

Galectin Therapeutics Inc. (Nasdaq: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company's abstract titled "Early phase 1 clinical trial results of GR-MD-02, a galectin-3 inhibitor, in patients having non-alcoholic steatohepatitis (NASH) with advanced fibrosis" was accepted as an oral presentation at The Liver Meeting, the 65th Annual Meeting of the American Association for the Study of Liver Diseases. The presentation will be made on Sunday, November 9, 2014 at 3:30pm Eastern Standard Time at the Hynes Convention Center in Boston, Mass.

Stephen A. Harrison, MD, Chief of Hepatology at Brooke Army Medical Center in San Antonio, Texas, will present the data during a session titled "Parallel 8: Novel Approaches in Diagnosis and Treatment in NAFLD and NASH." Dr. Harrison is a clinical trial investigator in Galectin Therapeutics' ongoing Phase 1 clinical trial of GR-MD-02 in NASH (fatty liver disease) patients with advanced fibrosis. The data presented will include the completed cohorts 1 and 2 of the Phase 1 trial and interim results of cohort 3.

According to Dr. Peter G. Traber, President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics Inc., "NASH with fibrosis is a significant unmet medical need for which effective therapies are limited. Acceptance of our data for an oral presentation at AASLD highlights the scientific and medical communities' deep interest in learning about new potential therapies for liver disease. We believe that GR-MD-02, our proprietary galectin-3 inhibitor, holds immense promise as a treatment option for fibrosis and inflammation."

The abstract is available at www.aasld.org.

半乳糖凝集素治疗公司（纳斯达克股票代码：高尔特），针对半乳糖凝集素蛋白质来治疗纤维化和癌症治疗的领先开发商，今天宣布，该公司的摘要标题为“GR-MD-02的早期阶段的临床试验结果中，半乳糖凝集素-3抑制剂，具有非酒精性脂肪性肝炎（NASH）与晚期肝纤维化患者的“被接受为口头介绍，在肝脏会议，美国协会的第65届年会上肝病的研究。该报告将提出在周日，2014年11月9日下午3:30东部标准时间在海因斯会议中心在波士顿。

斯蒂芬·哈里森博士，肝病的院长在布鲁克陆军医疗中心在圣安东尼奥，德克萨斯州，将在会议期间题为呈现数据“并行8：诊断和治疗新方法在NAFLD和NASH”哈里森博士是GR-MD-02的史蒂夫 - 纳什（脂肪肝）患者肝纤维化的半乳糖凝集素疗法“正在进行Ⅱ期临床试验临床试验研究者。给出的数据将包括完成队列1和2的第1阶段试验和队列3的中期业绩。

据医生彼得G.特拉伯，总裁，首席执行官和首席医疗官半乳糖凝集素Therapeutics公司的，“纳什纤维化是一种显著未满足的医疗需求的有效的治疗方法是有限的。接受我们的数据的口头介绍在AASLD突出了科学界和医学界对学习有关肝病的新的潜在治疗方法的浓厚兴趣，我们相信，GR-MD-02，我们专有的半乳糖凝集素-3抑制剂，拥有巨大的承诺，为肝纤维化和炎症的治疗选择。“

本摘要可在www.aasld.org。

使命123

是不是治疗脂肪肝和肝硬化的？

StephenW

使命123 发表于 2014-10-6 11:20
是不是治疗脂肪肝和肝硬化的？

治疗肝纤维化.